The POISE-3 trial, involving 9,535 patients from 22 countries, has delivered compelling statistical evidence supporting tranexamic acid’s effectiveness in major surgery. The key finding: an 11% reduction in composite bleeding outcomes when patients received the antifibrinolytic medication versus placebo (9.1% versus 10.3%). This represents more than 1,100 patients who avoided significant bleeding complications through a single, low-cost intervention. Additionally, patients treated with tranexamic acid required fewer red blood cell transfusions and experienced reduced overall blood loss. Importantly, the treatment did not increase rates of blood clots or other thromboembolic complications, establishing it as a safe addition to surgical protocols. These results underscore the power of evidence-based medicine in identifying cost-effective solutions for improving patient outcomes.
Was this article helpful?
